Die Anwendung von selektiven Progesteron-Rezeptor-Modulatoren (SPRMs) zur medikamentösen Behandlung von Uterusmyomen: Ulipristalacetat im Fokus // The Administration of SPERMs for the Medical Treatment

[1]  T. Römer.  Langzeitintervalltherapie mit Ulipristalacetat vermeidet Hysterektomie , 2017, Journal für Gynäkologische Endokrinologie/Schweiz.

[2]  F. Fischl.  Aktuelles: Ulipristalacetat (UPA) zur konservativen Myomtherapie und Blutungskontrolle bei Uterus myomatosus , 2017 .

[3]  J. Donnez,et al.  Uterine fibroid management: from the present to the future , 2016, Human reproduction update.

[4]  T. Rabe,et al.  Prevalence of uterine myomas in women in Germany: data of an epidemiological study , 2016, Archives of Gynecology and Obstetrics.

[5]  P. Saunders,et al.  Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies , 2016, Expert Opinion on Therapeutic Targets.

[6]  O. Ortmann,et al.  Selektive Progesteronrezeptormodulatoren , 2016, Gynäkologische Endokrinologie.

[7]  J. Donnez,et al.  The place of selective progesterone receptor modulators in myoma therapy. , 2016, Minerva ginecologica.

[8]  J. Donnez,et al.  Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators , 2015, Current opinion in obstetrics & gynecology.

[9]  E. Marbaix,et al.  In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. , 2015, Fertility and sterility.

[10]  K. König,et al.  Intermittierende Gabe von Ulipristalacetat zur konservativen Myomtherapie und Blutungskontrolle bei Hypermenorrhoe durch Uterus myomatosus Gemeinsame Stellungnahme der DGGGEF e.V. und des BVF e.V. , 2015 .

[11]  D. Luton,et al.  Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence , 2015, International journal of women's health.

[12]  I. Osterloh,et al.  Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. , 2015, Fertility and sterility.

[13]  C. Allaire,et al.  The management of uterine leiomyomas. , 2015, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[14]  I. Osterloh,et al.  Long-term treatment of uterine fibroids with ulipristal acetate ☆. , 2014, Fertility and sterility.

[15]  J. Kim,et al.  The role of progesterone signaling in the pathogenesis of uterine leiomyoma , 2012, Molecular and Cellular Endocrinology.

[16]  I. Osterloh,et al.  Ulipristal acetate versus leuprolide acetate for uterine fibroids. , 2012, The New England journal of medicine.

[17]  I. Osterloh,et al.  Ulipristal acetate versus placebo for fibroid treatment before surgery. , 2012, The New England journal of medicine.

[18]  B. Fauser,et al.  Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. , 2011, Fertility and sterility.

[19]  M. Broder,et al.  FIGO classification system (PALM‐COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age , 2011, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[20]  N. Chabbert-Buffet,et al.  Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. , 2007, The Journal of clinical endocrinology and metabolism.

[21]  N. Chabbert-Buffet,et al.  Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. , 2005, Human reproduction update.

[22]  D. Barlow,et al.  Long-term medical management of uterine fibroids with ulipristal acetate. , 2016, Fertility and sterility.

[23]  W. Catherino,et al.  Uterine fibroids , 2016, Nature Reviews Disease Primers.

[24]  J. Dungan.  Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids , 2012 .